Adam Feuerstein

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.

 


Feuerstein graduated from Emory University with a bachelor's degree in political science.

 


Recent Articles By The Author

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.

Puma Bio FDA Advisory Panel Live Blog

Puma Bio FDA Advisory Panel Live Blog

An FDA advisory panel is reviewing Puma's breast cancer drug neratinib.

Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote

Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote

The lack of "OMG" bombshells in the FDA's neratinib review are a Monday win for Puma bulls, and the stock is soaring.

Amgen Osteoporosis Drug Approval Plan Derailed Over Heart Safety Risk -- Jim Cramer Weighs In

Amgen Osteoporosis Drug Approval Plan Derailed Over Heart Safety Risk -- Jim Cramer Weighs In

Amgen's osteoporosis setback will likely be seen as providing a commercial boost to Radius Health, which secured U.S. approval in April for a competing osteoporosis drug, Tymlos.

Mixed Outcomes for La Jolla Pharma Shock Drug Fuels Debate Over Sales Potential

Mixed Outcomes for La Jolla Pharma Shock Drug Fuels Debate Over Sales Potential

LJPC-501 reversed dangerously low blood pressure in patients suffering from a severe form of shock, but the drug did not improve total organ function or reduce mortality.